ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal therapy that is being developed in atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune conditions. It has a joint venture with JAGUAHR Therapeutics Pte. Ltd. and Bukwang Pharmaceutical Co., Ltd. to develop immuno-oncology therapeutics for markets targeting the AhR pathway. Its partners include Almirall, Array BioPharma, and CSL Limited. The company was founded in 2010 and is headquartered in Singapore.
Year | Receivables | Debt | Liabilities | Assets | Current Assets |
---|---|---|---|---|---|
2023 | 171.44 K | 5.57 M | 37.91 M | 24.63 M | 24.13 M |
2022 | -19,281,442 | 52.82 M | 61.19 M | 60.88 M | |
2021 | -59,111,535 | 37.21 M | 94.52 M | 93.78 M | |
2020 | 528.84 K | 4.93 M | 26.23 M | 16.08 M | 15.5 M |
2019 | -3,816,172 | 23.95 M | 23.35 M | 22.27 M |